Close

Cempra (CEMP) Added to Focus List at Roth Capital

July 14, 2015 8:02 AM EDT
Get Alerts CEMP Hot Sheet
Price: $2.33 --0%

Rating Summary:
    1 Buy, 14 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

Roth Capital analyst Debjit Chattopadhyay added Cempra, Inc. (NASDAQ: CEMP) to its Focus List. The firm maintained a Buy rating and price target of $42.

Chattopadhyay commented, "Based on the robust readout from the Solitaire Oral study, expectations have ratcheted higher heading into the IV data (expected during 4Q). A statistically-significant benefit (older, sicker patients) could be a big win, with positive ramifications for pricing and adoption especially in the hospital setting, in our view. Solithromycin (pediatric, COPD, gonorrhea, NASH) or Taksta (ABSSI, B&J infections) are compelling opportunities and not reflected in the stock, in our opinion."

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $36.14 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Roth Capital